NEUP logo

NEUPHORIA THERAPEUTICS INC

NEUPNASDAQ
🏆 #4789 by market capUS Equity
$298.64▲ $2.72 (+0.91%)
Simulated price
🔔
Track NEUP
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.9%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$20M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
16.8x
Expensive
Otter Score
72
Fair
No chart data available for NEUP.

Trading Snapshot

Day Range
$296.28 – $299.88
52-Week Range
$3.19 – $21.40
Volume
$3.33B
Avg Volume
$2.86B
Shares Outstanding
5.4M
Next Earnings
Dec 11, 2026

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$290,773
P/E Ratio
—
P/S Ratio
16.8x
EPS (TTM)
$-5.00
Dividend Yield
—

Why Investors Own NEUP

  • ✓High-growth profile — revenue up +23.2% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 44% gross margin and 7% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NEUP logo

NEUPHORIA THERAPEUTICS INC

NEUP
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$1M▲ +26.0% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
44.3%▲ +0.8% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$440,313▲ +26.0% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$81,018▲ +26.0% YoY
StockOtter · stockotter.space

About NEUPHORIA THERAPEUTICS INC

Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$371.27
▲ +24.3% Upside
High Target$420.72
Low Target$303.92
Based on 34 analysts

Latest News & Updates

🚀
Reuters·2h ago

NEUPHORIA THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift NEUP price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

NEUPHORIA THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.